Kolexia
Attal Michel Médecine générale
Attal Michel
Médecine générale
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
329 Activités
54 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Récidive tumorale locale Maladie résiduelle Translocation génétique Leucémie aigüe myéloïde Aberrations des chromosomes Leucémies Lymphomes

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Avet-Loiseau Herve
Avet-Loiseau Herve
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Celgene
1 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
DFCI 10-106: A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Essai Clinique (Paul Richardson, MD)   27 novembre 2023
ICARIA-MM: A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Essai Clinique (Sanofi)   14 novembre 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica   01 mai 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
British journal of haematology   27 mars 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.
Haematologica   01 juillet 2022
Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
2022 ASCO Annual Meeting II   08 juin 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
The New England journal of medicine   05 juin 2022